Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases. Symvivo’s bacTRL™ platform technology delivers plasmid DNA, both orally and through IV administration, that enables a patient’s own cells to produce biologics. Symvivo is advancing therapeutics in the area of oral vaccines, oncology, immunology, and biologics.
British Columbia Institute Of Technology, 3700, Willingdon Avenue, Garden Village, Burnaby, Metro Vancouver Regional District, British Columbia, V5G 3H6, Canada
